These observations are consistent with the conclusion that the Tgfβ-RII mutation enhances tumor aggressiveness but not overall tumor initiation and progression, or ultimately survival of tumorigenesis driven by VpC-Msh2. The gene discussed is TGFB1; the disease is neoplasm.